Wielscher et al. (2026)
- Authors: Matthias Wielscher, Leonardo Vincenzi, Wolfgang P. Weninger, Eva S. Schernhammer
- Institutes: Center for Public Health, Medical University of Vienna, Vienna, Austria, Department of Dermatology, Medical University of Vienna, Vienna, Austria
- Publisher: Research Square
- Link: DOI
Summary
This large-scale genetic study identifies mitochondrial DNA and platelet characteristics as potentially causal factors in ME/CFS, moving beyond simple associations. By linking the disease to specific, measurable genetic traits, it provides a biological roadmap for developing objective diagnostic tests and exploring repurposed drugs that target these pathways. The findings reinforce the multisystem nature of the illness and offer concrete mechanistic leads for future therapeutic trials.
What was researched?
The study used genetic data from the DecodeME project to investigate whether specific biological processes, such as immune dysfunction or metabolic abnormalities, play a causal role in the development of ME/CFS.
Why was it researched?
While ME/CFS is known to involve multisystem abnormalities, it has been unclear which processes are causal drivers of the disease and which are merely downstream effects or symptoms.
How was it researched?
Researchers analyzed genome-wide summary statistics from 15,579 ME/CFS cases and 259,909 controls of European ancestry. They applied genetic correlation, pleiotropic heritability, and Mendelian randomization to evaluate 22 traits across domains including cellular energetics, neurovascular regulation, and barrier–microbiome function.
What has been found?
The study found strong genetic overlap between ME/CFS and conditions like migraine and irritable bowel syndrome, as well as cellular energetics. Mendelian randomization identified three potential causal factors: higher mitochondrial DNA copy number was protective, while increased glycoprotein acetyls and mean platelet volume increased the risk.
Discussion
The results suggest that ME/CFS susceptibility is driven by an interaction between barrier-microbiome dysfunction, neurovascular instability, and impaired energy metabolism. A limitation is the reliance on summary statistics, which may not capture the full heterogeneity of all patient subgroups.
Conclusion & Future Work
The findings identify specific causal pathways and biomarkers, providing a genetic foundation for future diagnostic tools and targeted therapies. Future research should explore how modulating these pathways, particularly mitochondrial and platelet function, could improve patient outcomes.